🟢 Eli Lilly surges 4.4% after presenting highly positive Phase 3 data for new obesity drugs

Eli Lilly and Company (LLY) is trading at $1181.00 (+4.4%) in pre-market sessions, driven by the release of highly positive new clinical data for its next-generation obesity treatments over the weekend.

• At the American Diabetes Association's annual meeting, Lilly presented compelling new Phase 3 results for retatrutide, showing it delivered up to 28.3% average weight loss over 80 weeks.
• The trial data also showed retatrutide significantly improved related conditions, reducing osteoarthritis knee pain by 73% and sleep apnea severity by 60%.
• Separately, new data for the oral GLP-1 drug Foundayo (orforglipron) demonstrated significant weight loss in women across all stages of menopause.